published meta-analysis   sensitivity analysis   studies

hydroxychloroquine in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.80[0.52; 1.24]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable deathsdetailed resultsDuke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56] Galan, 2021 (REV) 1.06 [0.58; 1.95] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Mahevas, 2020 0.61 [0.13; 2.88] Yu, 2020 0.32 [0.16; 0.63] 0.66[0.41; 1.09]Duke University hydroxychloroquine/azithromycine, 2020, Galan, 2021 (REV), HYDRA (Hernandez-Cardenas), 2021, Mahevas, 2020, Yu, 2020546%1,044seriousnot evaluable deaths (time to event analysis only)detailed resultsGalan, 2021 (REV) 1.06 [0.58; 1.95] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Yu, 2020 0.32 [0.16; 0.63] 0.67[0.36; 1.25]Galan, 2021 (REV), HYDRA (Hernandez-Cardenas), 2021, Yu, 2020373%950seriousnot evaluable clinical deteriorationdetailed resultsMahevas, 2020 0.93 [0.48; 1.81] 0.93[0.48; 1.81]Mahevas, 202010%NAnot evaluable clinical improvement (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] 1.05[0.74; 1.48]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable hospital dischargedetailed resultsHYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] 1.01[0.72; 1.42]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable mechanical ventilationdetailed resultsGalan, 2021 (REV) 7.21 [1.40; 37.04] 7.21[1.40; 37.04]Galan, 2021 (REV)10%168NAnot evaluable ICU admissiondetailed resultsGalan, 2021 (REV) 0.70 [0.33; 1.48] 0.70[0.33; 1.48]Galan, 2021 (REV)10%168NAnot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable0.510.01.0relative treatment effectwww.metaEvidence.org2024-06-24 11:47 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 657,832 - roots T: 290